Skip to main content
SpringerLink
Log in

Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

Intravenous immunoglobulin (IVIg) is a safe preparation made from human plasma. The original concept of IVIg as an anticancer drug was built up over the years, after numeral reports were accumulated indicating cancer regressions after IVIg administration. Because IVIg is basically an established remedy for immunodeficiencies and several autoimmune diseases, the association between beneficial effects in cancer patients after IVIg was first seen in patients who had both cancer and autoimmune or immunodeficiency diseases.

Interestingly, cancer and autoimmunity share several common features, which together enhance the notion of using IVIg to treat cancer.

Several studies tested the broad range of the antimetastatic effects of IVIg. IVIg was found to operate in many different and complex ways, among them (a) induction of interleukin-12 secretion, leading to natural-killer-cell activation; (b) inhibition of matrix metalloproteinase-9 mRNA expression; (c) suppression of tumor cell growth; (d) hindrance of nuclear factor κB activation and IκB degradation; and (e) G1 cell-cycle arrest.

In conclusion, IVIg is a potential anticancer treatment for several reasons: (a) the bidirectional relationship between cancer and autoimmunity; (b) the apparent association between cancer regression and IVIg administration; (c) a variety of anticancer effects of IVIg observed; and (d) IVIg is considered to be a safe preparation with minimal side effects. Obviously, prospective controlled studies that will establish the antitumor effects of IVIg are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fishman, P., Bar-Yehuda, S., and Shoenfeld, Y. (2002), Int J Oncol 21, 875–880.

    PubMed  CAS  Google Scholar 

  2. Kazatchkine, M. D. and Kaveri, S. V. (2001), N Engl J Med 345, 747–755.

    Article  PubMed  CAS  Google Scholar 

  3. Marinos, C., Dalakas, M. C., and Spath, P. J. In: Marinos, C., Dalakas, M. C., Spath, P. J., eds. Intravenous Immunoglobulins in the Third Millennium. New York/London: Parthenon Publishing Group, 2004, pp. 1–409.

    Google Scholar 

  4. Segal, E. and Shoenfeld, Y. (2001), Harefuah 140, 955–958.

    PubMed  CAS  Google Scholar 

  5. Dalakas, M. C. (1997), Ann Intern Med 126, 721–730.

    PubMed  CAS  Google Scholar 

  6. Shoenfeld, Y. and Fishman, P. (1999), Int Immunol. 11, 1247–1252.

    Article  PubMed  CAS  Google Scholar 

  7. Tomer, Y. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp. 141–150.

    Google Scholar 

  8. Tishler, M. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp. 121–132.

    Google Scholar 

  9. Sherer, Y. and Shoenfeld, Y. In: Shoenfeld, Y., Gershwin, E. M., eds. Cancer and Autoimmunity. Amsterdam: Elsevier, 2000, pp. 249–252.

    Google Scholar 

  10. Huminer, D., Tomer, Y., Pitlick, S., and Shoenfeld, Y. (1991), Autoimmunity 5, 232–233.

    Google Scholar 

  11. Swissa, M., Cohen, Y., and Shoenfeld, Y. (1990), Cancer 65, 2554–2558.

    Article  PubMed  CAS  Google Scholar 

  12. Shoenfeld, Y. and Isenberg, D. A. (1989), Immunol Today 10, 123–126.

    Article  PubMed  CAS  Google Scholar 

  13. Shoenfeld, Y., Kennedy, R., Ferrano, S., eds. (1997), Idiotypes in Autoimmunity, Infectious Diseases and Cancer. Amsterdam: Elsevier.

    Google Scholar 

  14. Shapiro, S., Shoenfeld, Y., Gilburd, B., Sobel, E., and Lahat, N. (2002), Cancer 95, 2032–2037.

    Article  PubMed  CAS  Google Scholar 

  15. Vassilev, T. L., Kazatchkine, M. D., Van Huyen, J. P., et al. (1999), Blood 93, 3624–3631.

    PubMed  CAS  Google Scholar 

  16. Ichiyama, T., Ueno, Y., Isumi, H., Niimi, A., Matsubara, T., and Furukawa, S. (2004), Inflamm Res 53, 253–256.

    Article  PubMed  CAS  Google Scholar 

  17. Ekberg, C., Nordstrom, E., Skansen-Saphir, U., et al. (2001), Hum Immunol. 62, 215–227.

    Article  PubMed  CAS  Google Scholar 

  18. Besa, E. C. (1984), Am J Med 76, 209–218.

    Article  PubMed  CAS  Google Scholar 

  19. Carmeli, Y., Mevorach, D., Kaminski, N., Raz, E. (1994), Cancer 73, 2859–2861.

    Article  PubMed  CAS  Google Scholar 

  20. Shoenfeld, Y., Levy, Y., and Fishman, P. (2001), IMAJ 3, 698–699.

    PubMed  CAS  Google Scholar 

  21. Merimsky, O., Meller, I., Inbar, M., Bar-Yehuda, S., Shoenfeld, Y., and Fishman, P. (2002), Int J Oncol. 20, 839–843.

    PubMed  CAS  Google Scholar 

  22. Sipak-Szmigiel, O., Ronin-Walknowska, E., and Miklaszwicz, A. (2003), Ginekol Pol 74, 350–355.

    PubMed  Google Scholar 

  23. US Patent no. 5,562,902. (1996), Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin.

  24. US Patent no 5,965,130. (1999), Immunotherapeutic method of treating cancerous diseases by administration of intravenous immunoglobulin.

  25. Bar-Dayan, Y., Barshack, I., Blank, M., et al. (1999), Int J Oncol. 15, 1091–1096.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine B and Research Center for Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel

    Tal Sapir & Yehuda Shoenfeld

  2. Life-Sciences Faculty, Bar-Ilan University, Ramat Gan, Israel

    Tal Sapir

  3. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Yehuda Shoenfeld

  4. Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmunity Diseases, Tel Aviv University, Tel Aviv, Israel

    Yehuda Shoenfeld

Authors
  1. Tal Sapir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yehuda Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yehuda Shoenfeld.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sapir, T., Shoenfeld, Y. Uncovering the hidden potential of intravenous immunoglobulin as an anticancer therapy. Clinic Rev Allerg Immunol 29, 307–310 (2005). https://doi.org/10.1385/CRIAI:29:3:307

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/CRIAI:29:3:307

Index Entries

Search

Navigation